Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cronos Group Inc. (CRON.TO)
CAD3.91
+0.02 (+0.51%)
CA TSX Healthcare Drug Manufacturers - Specialty & Generic
Address
111 Peter Street M5V 2H1
Stayner, ON, CA
Stayner, ON, CA
CEO
Michael Ryan Gorenstein
Website
thecronosgroup.com
IPO
2014-12-17
ISIN CA22717L1013
Also trades on
NASDAQ Global Market · CRON (USD)
Toronto Stock Exchange · CRON.TO (CAD)
Description
Cronos Group Inc. functions as a diversified global cannabinoid enterprise. Within the United States, it manufactures, promotes, and distributes a variety of hemp-derived supplements and cosmetic products. These items are available under its Lord Jones and Happy Dance brands through online sales, traditional retail, and hospitality partner networks. The company also plays a significant role in the cultivation, production, and commercialization of cannabis and cannabis-infused products for both medicinal and adult-use sectors. Its comprehensive product offerings encompass dried cannabis flower, pre-rolled joints, edibles, concentrated forms, and cannabis extracts. These are distributed via wholesale partnerships and direct-to-consumer channels, prominently featuring its wellness platform, PEACE NATURALS, and its adult-use brand, Spinach. Moreover, Cronos Group exports dried cannabis and cannabis oils to international markets including Germany, Israel, and Australia. Established in 2012, the company maintains its corporate headquarters in Toronto, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD3.91
+0.02 (+0.51%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
186.7K
Beta
1.25
Float Shares
193.56M
Free Float %
51.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.07% | +5.04% | +4.75% | +6.53% | +5.34% | +4.17% | +31.12% | +61.64% | -56.85% | +1,604.55% | +368.75% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (12 ratings, all time)
Hold
Price Targets & DCF
Current price
3.91
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
14.51
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+26.9% ★ Q1'26: +36.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-124.1% Q1'26: +119.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-25.8% Q1'26: +20.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-12.0% Q1'26: -3.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-5.7% Q1'26: -1.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.3% Q1'26: +24.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.80× Q1'26: -0.23× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.46M
est: 150.8K (+1,529.9%)
|
409.8K
est: 573.8K (-28.6%)
|
3.11M
est: 3.85M (-19.2%)
|
13.09M
est: 17.23M (-24.0%)
|
23.16M
est: 33.44M (-30.7%)
|
46.57M
est: 43.70M (+6.6%)
|
64.02M
est: 70.99M (-9.8%)
|
87.54M
est: 95.08M (-7.9%)
|
87.03M
est: 74.44M (+16.9%)
|
117.50M
est: 122.03M (-3.7%)
|
149.15M
est: 138.84M (+7.4%)
|
187.60M
164.44M – 199.59M
+35.1% YoY
|
211.50M
166.42M – 234.85M
+12.7% YoY
|
211.03M
184.98M – 224.53M
-0.2% YoY
|
184.67M
161.87M – 196.48M
-12.5% YoY
|
193.90M
169.96M – 206.30M
+5.0% YoY
|
| EBITDA |
404.2K
est: -127.2K (+417.9%)
|
-1.29M
est: -483.9K (-167.4%)
|
-5.29M
est: -3.25M (-63.0%)
|
-20.09M
est: -14.53M (-38.3%)
|
-145.82M
est: -28.20M (-417.2%)
|
-173.09M
est: -36.86M (-369.6%)
|
-150.79M
est: -59.87M (-151.9%)
|
-93.81M
est: -80.18M (-17.0%)
|
-72.28M
est: -48.22M (-49.9%)
|
-45.37M
est: -79.05M (+42.6%)
|
-3.36M
est: -89.94M (+96.3%)
|
-121.53M
-129.30M – -106.53M
-35.1% YoY
|
-137.01M
-152.14M – -107.81M
-12.7% YoY
|
-136.71M
-145.45M – -119.83M
+0.2% YoY
|
-119.63M
-127.28M – -104.86M
+12.5% YoY
|
-125.61M
-133.65M – -110.11M
-5.0% YoY
|
| EBIT |
322.4K
est: -132.0K (+344.2%)
|
-1.58M
est: -502.3K (-213.8%)
|
-6.05M
est: -3.37M (-79.5%)
|
-22.09M
est: -15.08M (-46.5%)
|
-149.52M
est: -29.27M (-410.8%)
|
-178.80M
est: -38.26M (-367.3%)
|
-164.15M
est: -62.15M (-164.1%)
|
-105.34M
est: -83.24M (-26.5%)
|
-79.72M
est: -52.06M (-53.1%)
|
-54.21M
est: -85.34M (+36.5%)
|
-17.84M
est: -97.10M (+81.6%)
|
-131.20M
-139.59M – -115.01M
-35.1% YoY
|
-147.92M
-164.25M – -116.40M
-12.7% YoY
|
-147.59M
-157.03M – -129.37M
+0.2% YoY
|
-129.15M
-137.41M – -113.21M
+12.5% YoY
|
-135.61M
-144.29M – -118.87M
-5.0% YoY
|
| Net Income |
278.7K
est: -17.29M (+101.6%)
|
-880.2K
est: -11.45M (+92.3%)
|
-1.47M
est: -3.92M (+62.6%)
|
-23.37M
est: -17.44M (-34.0%)
|
1.14B
est: 628.54M (+81.0%)
|
-72.90M
est: 11.02M (-761.6%)
|
-392.81M
est: -104.23M (-276.9%)
|
-170.26M
est: -110.55M (-54.0%)
|
-73.79M
est: -41.96M (-75.8%)
|
41.04M
est: -23.35M (+275.8%)
|
-9.61M
est: -921.6K (-943.0%)
|
21.70M
18.95M – 24.45M
+2,454.9% YoY
|
43.18M
37.53M – 48.84M
+99.0% YoY
|
50.64M
44.22M – 57.06M
+17.3% YoY
|
56.44M
47.38M – 61.13M
+11.5% YoY
|
63.97M
53.70M – 69.29M
+13.3% YoY
|
| SGA |
1.40M
est: 223.6K (+527.9%)
|
2.77M
est: 851.0K (+225.2%)
|
7.19M
est: 5.71M (+26.0%)
|
25.97M
est: 25.55M (+1.6%)
|
113.27M
est: 49.59M (+128.4%)
|
129.89M
est: 64.82M (+100.4%)
|
120.67M
est: 105.29M (+14.6%)
|
101.64M
est: 141.02M (-27.9%)
|
80.74M
est: 76.37M (+5.7%)
|
76.74M
est: 125.19M (-38.7%)
|
75.01M
est: 142.44M (-47.3%)
|
192.46M
168.70M – 204.77M
+35.1% YoY
|
216.98M
170.74M – 240.94M
+12.7% YoY
|
216.50M
189.77M – 230.35M
-0.2% YoY
|
189.45M
166.07M – 201.57M
-12.5% YoY
|
198.93M
174.37M – 211.65M
+5.0% YoY
|
| EPS |
0.01
est: -0.05 (+116.9%)
|
-0.01
est: -0.03 (+62.5%)
|
-0.01
est: -0.01 (-5.7%)
|
-0.13
est: -0.05 (-177.4%)
|
3.67
est: 1.64 (+123.1%)
|
-0.20
est: 0.03 (-806.4%)
|
-0.34
est: -0.27 (-23.6%)
|
-0.42
est: -0.27 (-53.0%)
|
-0.18
est: -0.11 (-64.3%)
|
0.10
est: -0.06 (+264.6%)
|
-0.03
est: 0.00 (-904.0%)
|
0.06
0.05 – 0.06
+2,454.9% YoY
|
0.11
0.10 – 0.13
+83.3% YoY
|
0.14
0.12 – 0.15
+27.3% YoY
|
0.15
0.12 – 0.16
+7.1% YoY
|
0.17
0.14 – 0.18
+13.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
78.12M
OE per share TTM
0.20
Owner's Yield
5.45%
Maintenance CapEx ratio
117.15%
Maint CapEx / Avg PPE
149.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 29 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares S&P/TSX SmallCap Index ETF XCS.TO | 0.25% | 432.8K | 0.60% |
| 2 | Desjardins RI Canada - Net-Zero Emissions Pathway ETF DRMC.TO | 0.01% | 6.6K | 0.15% |
| 3 | Vanguard MSCI International Small Cos Index ETF VISM.AX | 0.01% | 44.0K | 0.32% |
| 4 | Fidelity Nasdaq Composite Index ETF ONEQ | 0.01% | 598.4K | 0.21% |
| 5 | iShares MSCI World Small-Cap ETF WSML | 0.01% | 35.2K | 0.30% |
| 6 | State Street SPDR MSCI World Small Cap UCITS ETF (Acc) WDSC.L | 0.00% | 77.0K | 0.45% |
| 7 | iShares Core MSCI International Developed Markets ETF IDEV | 0.00% | 967.8K | 0.04% |
| 8 | iShares Core MSCI Total International Stock ETF IXUS | 0.00% | 1.76M | 0.07% |
| 9 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | 511.8K | 0.18% |
| 10 | iShares MSCI World Small Cap UCITS ETF WSML.L | 0.00% | 237.6K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-38.9K
Shares Outstanding
379.05M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Ryan Gorenstein | President, Chief Executive Officer & Chairman | 3M | male |
| Anna Shlimak | Chief Financial Officer | 1M | female |
| Jeffrey David Jacobson | Chief Growth Officer | 1M | male |
| James Holm | Executive Officer | 974.5K | male |
| Adam Wagner | General Manager of Cronos Israel | 872.0K | male |
| Shannon Buggy | Senior Vice President & Global Head of People | 725.3K | female |
| Terry Gregory-Joseph Doucet | General Counsel & Corporate Secretary | — | male |
| Arye Weigensberg | Senior Vice President and Head of Research & Development | — | male |
| Jared Matthew Kenost | Principal Accounting Officer, Vice President & Controller | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRON.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
